nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Docetaxel—pancreatic cancer	0.0642	0.109	CbGbCtD
Dabrafenib—ABCG2—Tamoxifen—pancreatic cancer	0.0528	0.0895	CbGbCtD
Dabrafenib—SLCO1B1—Irinotecan—pancreatic cancer	0.051	0.0865	CbGbCtD
Dabrafenib—ABCG2—Erlotinib—pancreatic cancer	0.0449	0.0761	CbGbCtD
Dabrafenib—ABCG2—Irinotecan—pancreatic cancer	0.0405	0.0688	CbGbCtD
Dabrafenib—ABCG2—Fluorouracil—pancreatic cancer	0.0389	0.066	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—pancreatic cancer	0.0297	0.0504	CbGbCtD
Dabrafenib—ABCG2—Sunitinib—pancreatic cancer	0.0296	0.0502	CbGbCtD
Dabrafenib—CYP2C8—Tamoxifen—pancreatic cancer	0.0281	0.0477	CbGbCtD
Dabrafenib—CYP2C8—Erlotinib—pancreatic cancer	0.0239	0.0406	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—pancreatic cancer	0.0221	0.0376	CbGbCtD
Dabrafenib—CYP2C8—Fluorouracil—pancreatic cancer	0.0207	0.0351	CbGbCtD
Dabrafenib—ABCB1—Tamoxifen—pancreatic cancer	0.019	0.0323	CbGbCtD
Dabrafenib—ABCB1—Gemcitabine—pancreatic cancer	0.0164	0.0278	CbGbCtD
Dabrafenib—ABCB1—Erlotinib—pancreatic cancer	0.0162	0.0275	CbGbCtD
Dabrafenib—ABCB1—Irinotecan—pancreatic cancer	0.0146	0.0248	CbGbCtD
Dabrafenib—CYP3A4—Tamoxifen—pancreatic cancer	0.0114	0.0193	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—pancreatic cancer	0.0107	0.0182	CbGbCtD
Dabrafenib—ABCB1—Sunitinib—pancreatic cancer	0.0107	0.0181	CbGbCtD
Dabrafenib—CYP3A4—Erlotinib—pancreatic cancer	0.0097	0.0164	CbGbCtD
Dabrafenib—CYP3A4—Irinotecan—pancreatic cancer	0.00876	0.0149	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—pancreatic cancer	0.00799	0.0135	CbGbCtD
Dabrafenib—CYP3A4—Docetaxel—pancreatic cancer	0.00642	0.0109	CbGbCtD
Dabrafenib—CYP3A4—Sunitinib—pancreatic cancer	0.00639	0.0108	CbGbCtD
Dabrafenib—RAF1—Topotecan—Irinotecan—pancreatic cancer	0.00513	1	CbGdCrCtD
Dabrafenib—CYP3A4—Doxorubicin—pancreatic cancer	0.00478	0.00811	CbGbCtD
Dabrafenib—Dermatitis—Tamoxifen—pancreatic cancer	0.00017	0.000712	CcSEcCtD
Dabrafenib—Vomiting—Erlotinib—pancreatic cancer	0.00017	0.000711	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000169	0.000708	CcSEcCtD
Dabrafenib—Headache—Tamoxifen—pancreatic cancer	0.000169	0.000708	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000169	0.000707	CcSEcCtD
Dabrafenib—Rash—Erlotinib—pancreatic cancer	0.000168	0.000705	CcSEcCtD
Dabrafenib—Dermatitis—Erlotinib—pancreatic cancer	0.000168	0.000704	CcSEcCtD
Dabrafenib—Angiopathy—Docetaxel—pancreatic cancer	0.000168	0.000704	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—pancreatic cancer	0.000168	0.000703	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—pancreatic cancer	0.000168	0.000702	CcSEcCtD
Dabrafenib—Insomnia—Gemcitabine—pancreatic cancer	0.000168	0.000702	CcSEcCtD
Dabrafenib—Immune system disorder—Docetaxel—pancreatic cancer	0.000167	0.0007	CcSEcCtD
Dabrafenib—Headache—Erlotinib—pancreatic cancer	0.000167	0.0007	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—pancreatic cancer	0.000167	0.0007	CcSEcCtD
Dabrafenib—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000167	0.000699	CcSEcCtD
Dabrafenib—Chills—Docetaxel—pancreatic cancer	0.000166	0.000696	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000166	0.000696	CcSEcCtD
Dabrafenib—Asthenia—Sunitinib—pancreatic cancer	0.000166	0.000694	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—pancreatic cancer	0.000165	0.000693	CcSEcCtD
Dabrafenib—Decreased appetite—Irinotecan—pancreatic cancer	0.000165	0.000693	CcSEcCtD
Dabrafenib—Arrhythmia—Docetaxel—pancreatic cancer	0.000165	0.000693	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000165	0.000691	CcSEcCtD
Dabrafenib—Insomnia—Fluorouracil—pancreatic cancer	0.000165	0.00069	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—pancreatic cancer	0.000164	0.000688	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000164	0.000688	CcSEcCtD
Dabrafenib—Fatigue—Irinotecan—pancreatic cancer	0.000164	0.000687	CcSEcCtD
Dabrafenib—Alopecia—Docetaxel—pancreatic cancer	0.000164	0.000685	CcSEcCtD
Dabrafenib—Pruritus—Sunitinib—pancreatic cancer	0.000163	0.000685	CcSEcCtD
Dabrafenib—Constipation—Irinotecan—pancreatic cancer	0.000163	0.000682	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000163	0.000681	CcSEcCtD
Dabrafenib—Mental disorder—Docetaxel—pancreatic cancer	0.000162	0.000679	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000161	0.000676	CcSEcCtD
Dabrafenib—Malnutrition—Docetaxel—pancreatic cancer	0.000161	0.000675	CcSEcCtD
Dabrafenib—Erythema—Docetaxel—pancreatic cancer	0.000161	0.000675	CcSEcCtD
Dabrafenib—Decreased appetite—Gemcitabine—pancreatic cancer	0.000161	0.000675	CcSEcCtD
Dabrafenib—Nausea—Tamoxifen—pancreatic cancer	0.00016	0.000671	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00016	0.00067	CcSEcCtD
Dabrafenib—Fatigue—Gemcitabine—pancreatic cancer	0.00016	0.000669	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000159	0.000667	CcSEcCtD
Dabrafenib—Constipation—Gemcitabine—pancreatic cancer	0.000159	0.000664	CcSEcCtD
Dabrafenib—Nausea—Erlotinib—pancreatic cancer	0.000159	0.000664	CcSEcCtD
Dabrafenib—Decreased appetite—Fluorouracil—pancreatic cancer	0.000158	0.000664	CcSEcCtD
Dabrafenib—Diarrhoea—Sunitinib—pancreatic cancer	0.000158	0.000662	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000157	0.000659	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000156	0.000655	CcSEcCtD
Dabrafenib—Back pain—Docetaxel—pancreatic cancer	0.000156	0.000653	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000156	0.000652	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—pancreatic cancer	0.000155	0.000651	CcSEcCtD
Dabrafenib—Muscle spasms—Docetaxel—pancreatic cancer	0.000155	0.000649	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—pancreatic cancer	0.000153	0.000641	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—pancreatic cancer	0.000153	0.000641	CcSEcCtD
Dabrafenib—Dizziness—Sunitinib—pancreatic cancer	0.000153	0.00064	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000153	0.000639	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000152	0.000637	CcSEcCtD
Dabrafenib—Abdominal pain—Irinotecan—pancreatic cancer	0.00015	0.00063	CcSEcCtD
Dabrafenib—Body temperature increased—Irinotecan—pancreatic cancer	0.00015	0.00063	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00015	0.00063	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000149	0.000626	CcSEcCtD
Dabrafenib—Anaemia—Docetaxel—pancreatic cancer	0.000149	0.000624	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000147	0.000617	CcSEcCtD
Dabrafenib—Vomiting—Sunitinib—pancreatic cancer	0.000147	0.000615	CcSEcCtD
Dabrafenib—Body temperature increased—Gemcitabine—pancreatic cancer	0.000147	0.000614	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—pancreatic cancer	0.000146	0.000611	CcSEcCtD
Dabrafenib—Rash—Sunitinib—pancreatic cancer	0.000146	0.00061	CcSEcCtD
Dabrafenib—Dermatitis—Sunitinib—pancreatic cancer	0.000146	0.00061	CcSEcCtD
Dabrafenib—Headache—Sunitinib—pancreatic cancer	0.000145	0.000606	CcSEcCtD
Dabrafenib—Leukopenia—Docetaxel—pancreatic cancer	0.000144	0.000604	CcSEcCtD
Dabrafenib—Body temperature increased—Fluorouracil—pancreatic cancer	0.000144	0.000603	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—pancreatic cancer	0.000142	0.000593	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000141	0.00059	CcSEcCtD
Dabrafenib—Cough—Docetaxel—pancreatic cancer	0.000141	0.000589	CcSEcCtD
Dabrafenib—Hypersensitivity—Irinotecan—pancreatic cancer	0.00014	0.000587	CcSEcCtD
Dabrafenib—Hypertension—Docetaxel—pancreatic cancer	0.000139	0.000583	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—pancreatic cancer	0.000139	0.000583	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—pancreatic cancer	0.000139	0.000583	CcSEcCtD
Dabrafenib—Myalgia—Docetaxel—pancreatic cancer	0.000137	0.000575	CcSEcCtD
Dabrafenib—Arthralgia—Docetaxel—pancreatic cancer	0.000137	0.000575	CcSEcCtD
Dabrafenib—Nausea—Sunitinib—pancreatic cancer	0.000137	0.000575	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—pancreatic cancer	0.000137	0.000573	CcSEcCtD
Dabrafenib—Asthenia—Irinotecan—pancreatic cancer	0.000137	0.000572	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000136	0.000571	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—pancreatic cancer	0.000136	0.000568	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—pancreatic cancer	0.000135	0.000566	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—pancreatic cancer	0.000135	0.000565	CcSEcCtD
Dabrafenib—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000134	0.000562	CcSEcCtD
Dabrafenib—Dry mouth—Docetaxel—pancreatic cancer	0.000134	0.000562	CcSEcCtD
Dabrafenib—Asthenia—Gemcitabine—pancreatic cancer	0.000133	0.000557	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—pancreatic cancer	0.000133	0.000556	CcSEcCtD
Dabrafenib—Oedema—Docetaxel—pancreatic cancer	0.000132	0.000551	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—pancreatic cancer	0.000131	0.00055	CcSEcCtD
Dabrafenib—Pruritus—Gemcitabine—pancreatic cancer	0.000131	0.000549	CcSEcCtD
Dabrafenib—Infection—Docetaxel—pancreatic cancer	0.000131	0.000547	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.00013	0.000545	CcSEcCtD
Dabrafenib—Diarrhoea—Irinotecan—pancreatic cancer	0.00013	0.000545	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—pancreatic cancer	0.000129	0.00054	CcSEcCtD
Dabrafenib—Pruritus—Fluorouracil—pancreatic cancer	0.000129	0.00054	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000129	0.000539	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—pancreatic cancer	0.000129	0.000539	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—pancreatic cancer	0.000129	0.000539	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—pancreatic cancer	0.000128	0.000535	CcSEcCtD
Dabrafenib—Diarrhoea—Gemcitabine—pancreatic cancer	0.000127	0.000531	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—pancreatic cancer	0.000127	0.00053	CcSEcCtD
Dabrafenib—Dizziness—Irinotecan—pancreatic cancer	0.000126	0.000527	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—pancreatic cancer	0.000126	0.000526	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—pancreatic cancer	0.000125	0.000526	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000125	0.000524	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—pancreatic cancer	0.000125	0.000523	CcSEcCtD
Dabrafenib—Diarrhoea—Fluorouracil—pancreatic cancer	0.000125	0.000522	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000123	0.000517	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—pancreatic cancer	0.000123	0.000515	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—pancreatic cancer	0.000123	0.000515	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—pancreatic cancer	0.000123	0.000514	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000123	0.000514	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—pancreatic cancer	0.000122	0.000513	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—pancreatic cancer	0.000121	0.000509	CcSEcCtD
Dabrafenib—Vomiting—Irinotecan—pancreatic cancer	0.000121	0.000507	CcSEcCtD
Dabrafenib—Dizziness—Fluorouracil—pancreatic cancer	0.000121	0.000505	CcSEcCtD
Dabrafenib—Rash—Irinotecan—pancreatic cancer	0.00012	0.000503	CcSEcCtD
Dabrafenib—Dermatitis—Irinotecan—pancreatic cancer	0.00012	0.000502	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00012	0.000502	CcSEcCtD
Dabrafenib—Headache—Irinotecan—pancreatic cancer	0.000119	0.000499	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—pancreatic cancer	0.000119	0.000498	CcSEcCtD
Dabrafenib—Vomiting—Gemcitabine—pancreatic cancer	0.000118	0.000494	CcSEcCtD
Dabrafenib—Rash—Gemcitabine—pancreatic cancer	0.000117	0.00049	CcSEcCtD
Dabrafenib—Dermatitis—Gemcitabine—pancreatic cancer	0.000117	0.000489	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—pancreatic cancer	0.000117	0.000489	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—pancreatic cancer	0.000116	0.000486	CcSEcCtD
Dabrafenib—Headache—Gemcitabine—pancreatic cancer	0.000116	0.000486	CcSEcCtD
Dabrafenib—Vomiting—Fluorouracil—pancreatic cancer	0.000116	0.000485	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—pancreatic cancer	0.000116	0.000484	CcSEcCtD
Dabrafenib—Rash—Fluorouracil—pancreatic cancer	0.000115	0.000481	CcSEcCtD
Dabrafenib—Dermatitis—Fluorouracil—pancreatic cancer	0.000115	0.000481	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—pancreatic cancer	0.000114	0.000479	CcSEcCtD
Dabrafenib—Headache—Fluorouracil—pancreatic cancer	0.000114	0.000478	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000114	0.000478	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000114	0.000477	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000114	0.000476	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000114	0.000476	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—pancreatic cancer	0.000113	0.000475	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—pancreatic cancer	0.000113	0.000475	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—pancreatic cancer	0.000113	0.000474	CcSEcCtD
Dabrafenib—Nausea—Irinotecan—pancreatic cancer	0.000113	0.000473	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—pancreatic cancer	0.000113	0.000472	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000113	0.000471	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—pancreatic cancer	0.000112	0.000471	CcSEcCtD
Dabrafenib—Chills—Epirubicin—pancreatic cancer	0.000112	0.000469	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—pancreatic cancer	0.000112	0.000467	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—pancreatic cancer	0.00011	0.000462	CcSEcCtD
Dabrafenib—Nausea—Gemcitabine—pancreatic cancer	0.00011	0.000461	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—pancreatic cancer	0.000109	0.000458	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—pancreatic cancer	0.000109	0.000455	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—pancreatic cancer	0.000109	0.000455	CcSEcCtD
Dabrafenib—Nausea—Fluorouracil—pancreatic cancer	0.000108	0.000453	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—pancreatic cancer	0.000108	0.000452	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000108	0.000451	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—pancreatic cancer	0.000105	0.00044	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—pancreatic cancer	0.000105	0.000439	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—pancreatic cancer	0.000105	0.000438	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—pancreatic cancer	0.000104	0.000437	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000104	0.000436	CcSEcCtD
Dabrafenib—Body temperature increased—Docetaxel—pancreatic cancer	0.000104	0.000436	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—pancreatic cancer	0.000104	0.000436	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—pancreatic cancer	0.000104	0.000434	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—pancreatic cancer	0.000103	0.000432	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—pancreatic cancer	0.000102	0.000429	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—pancreatic cancer	0.000102	0.000428	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—pancreatic cancer	0.000101	0.000424	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—pancreatic cancer	0.000101	0.000421	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—pancreatic cancer	0.000101	0.000421	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—pancreatic cancer	0.0001	0.000421	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—pancreatic cancer	9.73e-05	0.000408	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—pancreatic cancer	9.73e-05	0.000408	CcSEcCtD
Dabrafenib—Hypersensitivity—Docetaxel—pancreatic cancer	9.69e-05	0.000406	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—pancreatic cancer	9.67e-05	0.000405	CcSEcCtD
Dabrafenib—Cough—Epirubicin—pancreatic cancer	9.49e-05	0.000397	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—pancreatic cancer	9.48e-05	0.000397	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—pancreatic cancer	9.44e-05	0.000395	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—pancreatic cancer	9.39e-05	0.000393	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—pancreatic cancer	9.31e-05	0.00039	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—pancreatic cancer	9.3e-05	0.000389	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—pancreatic cancer	9.26e-05	0.000388	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—pancreatic cancer	9.26e-05	0.000388	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	9.19e-05	0.000385	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—pancreatic cancer	9.05e-05	0.000379	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—pancreatic cancer	9e-05	0.000377	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—pancreatic cancer	9e-05	0.000377	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—pancreatic cancer	8.87e-05	0.000372	CcSEcCtD
Dabrafenib—Infection—Epirubicin—pancreatic cancer	8.81e-05	0.000369	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—pancreatic cancer	8.78e-05	0.000368	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—pancreatic cancer	8.7e-05	0.000364	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—pancreatic cancer	8.7e-05	0.000364	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—pancreatic cancer	8.69e-05	0.000364	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—pancreatic cancer	8.68e-05	0.000364	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—pancreatic cancer	8.62e-05	0.000361	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—pancreatic cancer	8.58e-05	0.000359	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—pancreatic cancer	8.56e-05	0.000359	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—pancreatic cancer	8.56e-05	0.000359	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	8.5e-05	0.000356	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—pancreatic cancer	8.38e-05	0.000351	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—pancreatic cancer	8.36e-05	0.00035	CcSEcCtD
Dabrafenib—Rash—Docetaxel—pancreatic cancer	8.29e-05	0.000347	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—pancreatic cancer	8.29e-05	0.000347	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—pancreatic cancer	8.29e-05	0.000347	CcSEcCtD
Dabrafenib—Headache—Docetaxel—pancreatic cancer	8.24e-05	0.000345	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—pancreatic cancer	8.21e-05	0.000344	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—pancreatic cancer	8.16e-05	0.000342	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	8.08e-05	0.000339	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—pancreatic cancer	8.05e-05	0.000337	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—pancreatic cancer	8.04e-05	0.000337	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—pancreatic cancer	8.02e-05	0.000336	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—pancreatic cancer	7.97e-05	0.000334	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—pancreatic cancer	7.94e-05	0.000332	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—pancreatic cancer	7.81e-05	0.000327	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—pancreatic cancer	7.71e-05	0.000323	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—pancreatic cancer	7.67e-05	0.000321	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	7.66e-05	0.000321	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—pancreatic cancer	7.65e-05	0.00032	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—pancreatic cancer	7.59e-05	0.000318	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	7.48e-05	0.000313	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—pancreatic cancer	7.42e-05	0.000311	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—pancreatic cancer	7.26e-05	0.000304	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—pancreatic cancer	7.14e-05	0.000299	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	7.09e-05	0.000297	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—pancreatic cancer	7.08e-05	0.000296	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—pancreatic cancer	7.02e-05	0.000294	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—pancreatic cancer	7.01e-05	0.000294	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—pancreatic cancer	7.01e-05	0.000294	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	6.71e-05	0.000281	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—pancreatic cancer	6.54e-05	0.000274	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—pancreatic cancer	6.49e-05	0.000272	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—pancreatic cancer	6.49e-05	0.000272	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—pancreatic cancer	6.37e-05	0.000267	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—pancreatic cancer	6.28e-05	0.000263	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—pancreatic cancer	6.07e-05	0.000254	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—pancreatic cancer	6.05e-05	0.000253	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—pancreatic cancer	5.89e-05	0.000247	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—pancreatic cancer	5.87e-05	0.000246	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—pancreatic cancer	5.81e-05	0.000243	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—pancreatic cancer	5.64e-05	0.000236	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—pancreatic cancer	5.62e-05	0.000235	CcSEcCtD
Dabrafenib—Rash—Epirubicin—pancreatic cancer	5.59e-05	0.000234	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—pancreatic cancer	5.59e-05	0.000234	CcSEcCtD
Dabrafenib—Headache—Epirubicin—pancreatic cancer	5.56e-05	0.000233	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—pancreatic cancer	5.43e-05	0.000227	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—pancreatic cancer	5.27e-05	0.000221	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—pancreatic cancer	5.22e-05	0.000219	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—pancreatic cancer	5.18e-05	0.000217	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—pancreatic cancer	5.17e-05	0.000217	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—pancreatic cancer	5.14e-05	0.000215	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—pancreatic cancer	4.88e-05	0.000204	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways—TERT—pancreatic cancer	1.48e-05	8.91e-05	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—pancreatic cancer	1.48e-05	8.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMP—pancreatic cancer	1.47e-05	8.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TERT—pancreatic cancer	1.47e-05	8.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CG—pancreatic cancer	1.47e-05	8.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTEN—pancreatic cancer	1.46e-05	8.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GCG—pancreatic cancer	1.46e-05	8.75e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CG—pancreatic cancer	1.45e-05	8.71e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.45e-05	8.7e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.44e-05	8.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.44e-05	8.65e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—STK11—pancreatic cancer	1.43e-05	8.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—pancreatic cancer	1.43e-05	8.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HIF1A—pancreatic cancer	1.42e-05	8.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TSC2—pancreatic cancer	1.42e-05	8.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.41e-05	8.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SRC—pancreatic cancer	1.41e-05	8.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HIF1A—pancreatic cancer	1.4e-05	8.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—pancreatic cancer	1.4e-05	8.41e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—pancreatic cancer	1.4e-05	8.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—pancreatic cancer	1.4e-05	8.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TSC2—pancreatic cancer	1.4e-05	8.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.39e-05	8.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGTR1—pancreatic cancer	1.39e-05	8.35e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—pancreatic cancer	1.39e-05	8.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKBIA—pancreatic cancer	1.38e-05	8.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STK11—pancreatic cancer	1.37e-05	8.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—pancreatic cancer	1.37e-05	8.22e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CB—pancreatic cancer	1.37e-05	8.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GLP1R—pancreatic cancer	1.36e-05	8.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—pancreatic cancer	1.36e-05	8.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—pancreatic cancer	1.36e-05	8.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—pancreatic cancer	1.36e-05	8.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SRC—pancreatic cancer	1.36e-05	8.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.35e-05	8.08e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DPYD—pancreatic cancer	1.34e-05	8.04e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.33e-05	8.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—pancreatic cancer	1.33e-05	8.01e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TYMS—pancreatic cancer	1.33e-05	7.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGF—pancreatic cancer	1.32e-05	7.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—pancreatic cancer	1.32e-05	7.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—pancreatic cancer	1.3e-05	7.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—pancreatic cancer	1.3e-05	7.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKBIA—pancreatic cancer	1.29e-05	7.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CD—pancreatic cancer	1.29e-05	7.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH1—pancreatic cancer	1.28e-05	7.68e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CD—pancreatic cancer	1.28e-05	7.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	1.27e-05	7.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOTCH1—pancreatic cancer	1.26e-05	7.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.26e-05	7.55e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CG—pancreatic cancer	1.25e-05	7.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—pancreatic cancer	1.24e-05	7.43e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGF—pancreatic cancer	1.24e-05	7.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—pancreatic cancer	1.23e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TYMS—pancreatic cancer	1.23e-05	7.39e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.23e-05	7.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGF—pancreatic cancer	1.22e-05	7.34e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.21e-05	7.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—pancreatic cancer	1.21e-05	7.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMAD4—pancreatic cancer	1.2e-05	7.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.2e-05	7.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—pancreatic cancer	1.19e-05	7.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—pancreatic cancer	1.19e-05	7.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GLP1R—pancreatic cancer	1.19e-05	7.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.19e-05	7.12e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—pancreatic cancer	1.18e-05	7.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CD—pancreatic cancer	1.18e-05	7.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HES1—pancreatic cancer	1.17e-05	7.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—pancreatic cancer	1.17e-05	7.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DPYD—pancreatic cancer	1.17e-05	7.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—pancreatic cancer	1.15e-05	6.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—pancreatic cancer	1.12e-05	6.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.12e-05	6.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—pancreatic cancer	1.12e-05	6.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CB—pancreatic cancer	1.11e-05	6.68e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A2—pancreatic cancer	1.11e-05	6.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.11e-05	6.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—pancreatic cancer	1.1e-05	6.62e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—pancreatic cancer	1.1e-05	6.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CD—pancreatic cancer	1.1e-05	6.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SRC—pancreatic cancer	1.1e-05	6.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CD—pancreatic cancer	1.09e-05	6.52e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—pancreatic cancer	1.08e-05	6.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—pancreatic cancer	1.08e-05	6.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—pancreatic cancer	1.07e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—pancreatic cancer	1.06e-05	6.35e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—pancreatic cancer	1.06e-05	6.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.04e-05	6.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—pancreatic cancer	1.03e-05	6.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—pancreatic cancer	1.03e-05	6.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CB—pancreatic cancer	1.03e-05	6.16e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.02e-05	6.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1e-05	6.01e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—pancreatic cancer	1e-05	6.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—pancreatic cancer	9.93e-06	5.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—pancreatic cancer	9.93e-06	5.96e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD44—pancreatic cancer	9.84e-06	5.91e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—pancreatic cancer	9.83e-06	5.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—pancreatic cancer	9.82e-06	5.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—pancreatic cancer	9.81e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSC2—pancreatic cancer	9.8e-06	5.88e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—pancreatic cancer	9.75e-06	5.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—pancreatic cancer	9.74e-06	5.85e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.64e-06	5.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—pancreatic cancer	9.61e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—pancreatic cancer	9.61e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—pancreatic cancer	9.59e-06	5.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—pancreatic cancer	9.59e-06	5.76e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	9.55e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—pancreatic cancer	9.54e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—pancreatic cancer	9.47e-06	5.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GCG—pancreatic cancer	9.44e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—pancreatic cancer	9.41e-06	5.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—pancreatic cancer	9.4e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—pancreatic cancer	9.38e-06	5.63e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—pancreatic cancer	9.21e-06	5.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—pancreatic cancer	9.09e-06	5.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—pancreatic cancer	9.08e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMP—pancreatic cancer	9.07e-06	5.44e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—pancreatic cancer	9.03e-06	5.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKBIA—pancreatic cancer	8.94e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STK11—pancreatic cancer	8.87e-06	5.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—pancreatic cancer	8.86e-06	5.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—pancreatic cancer	8.85e-06	5.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—pancreatic cancer	8.82e-06	5.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—pancreatic cancer	8.77e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—pancreatic cancer	8.71e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—pancreatic cancer	8.65e-06	5.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—pancreatic cancer	8.65e-06	5.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—pancreatic cancer	8.58e-06	5.15e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD44—pancreatic cancer	8.58e-06	5.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—pancreatic cancer	8.57e-06	5.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGF—pancreatic cancer	8.56e-06	5.14e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—pancreatic cancer	8.5e-06	5.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—pancreatic cancer	8.42e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—pancreatic cancer	8.4e-06	5.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—pancreatic cancer	8.34e-06	5.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—pancreatic cancer	8.33e-06	5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.33e-06	5e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—pancreatic cancer	8.28e-06	4.97e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCG—pancreatic cancer	8.22e-06	4.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—pancreatic cancer	8.22e-06	4.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—pancreatic cancer	8.18e-06	4.91e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—pancreatic cancer	7.94e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—pancreatic cancer	7.93e-06	4.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—pancreatic cancer	7.91e-06	4.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—pancreatic cancer	7.89e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STK11—pancreatic cancer	7.73e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—pancreatic cancer	7.72e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—pancreatic cancer	7.68e-06	4.61e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—pancreatic cancer	7.63e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—pancreatic cancer	7.61e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—pancreatic cancer	7.59e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—pancreatic cancer	7.48e-06	4.49e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—pancreatic cancer	7.47e-06	4.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—pancreatic cancer	7.45e-06	4.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—pancreatic cancer	7.41e-06	4.45e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—pancreatic cancer	7.4e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—pancreatic cancer	7.39e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—pancreatic cancer	7.32e-06	4.39e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.31e-06	4.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—pancreatic cancer	7.3e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—pancreatic cancer	7.2e-06	4.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DPYD—pancreatic cancer	7.19e-06	4.32e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	6.92e-06	4.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—pancreatic cancer	6.88e-06	4.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—pancreatic cancer	6.87e-06	4.12e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—pancreatic cancer	6.85e-06	4.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.84e-06	4.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.82e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—pancreatic cancer	6.82e-06	4.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—pancreatic cancer	6.81e-06	4.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—pancreatic cancer	6.8e-06	4.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—pancreatic cancer	6.78e-06	4.07e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—pancreatic cancer	6.78e-06	4.07e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—pancreatic cancer	6.73e-06	4.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—pancreatic cancer	6.65e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—pancreatic cancer	6.65e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—pancreatic cancer	6.63e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—pancreatic cancer	6.46e-06	3.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—pancreatic cancer	6.37e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—pancreatic cancer	6.36e-06	3.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—pancreatic cancer	6.33e-06	3.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—pancreatic cancer	6.28e-06	3.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—pancreatic cancer	6.25e-06	3.75e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—pancreatic cancer	6.21e-06	3.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—pancreatic cancer	6.1e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—pancreatic cancer	5.98e-06	3.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—pancreatic cancer	5.94e-06	3.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—pancreatic cancer	5.88e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.88e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—pancreatic cancer	5.84e-06	3.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—pancreatic cancer	5.79e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—pancreatic cancer	5.77e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—pancreatic cancer	5.76e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—pancreatic cancer	5.73e-06	3.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—pancreatic cancer	5.65e-06	3.39e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	5.6e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—pancreatic cancer	5.59e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—pancreatic cancer	5.54e-06	3.32e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—pancreatic cancer	5.41e-06	3.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—pancreatic cancer	5.41e-06	3.25e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—pancreatic cancer	5.41e-06	3.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—pancreatic cancer	5.34e-06	3.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—pancreatic cancer	5.31e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD44—pancreatic cancer	5.28e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—pancreatic cancer	5.18e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—pancreatic cancer	5.13e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—pancreatic cancer	5.11e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—pancreatic cancer	5.11e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCG—pancreatic cancer	5.07e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	4.93e-06	2.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	4.88e-06	2.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—pancreatic cancer	4.77e-06	2.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STK11—pancreatic cancer	4.76e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—pancreatic cancer	4.76e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—pancreatic cancer	4.75e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—pancreatic cancer	4.72e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—pancreatic cancer	4.71e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—pancreatic cancer	4.66e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—pancreatic cancer	4.55e-06	2.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—pancreatic cancer	4.4e-06	2.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4.29e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.29e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	4.25e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	4.22e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.1e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—pancreatic cancer	4.04e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—pancreatic cancer	3.91e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—pancreatic cancer	3.74e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.74e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—pancreatic cancer	3.72e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—pancreatic cancer	3.71e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.71e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—pancreatic cancer	3.45e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—pancreatic cancer	3.33e-06	2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—pancreatic cancer	3.3e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—pancreatic cancer	3.23e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.01e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.9e-06	1.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.64e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.62e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.3e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.28e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.28e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—pancreatic cancer	2.14e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.99e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—pancreatic cancer	1.86e-06	1.12e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.4e-06	8.43e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.15e-06	6.89e-06	CbGpPWpGaD
